⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APRE News
Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
globenewswire.com
APRE
Form 8-K
sec.gov
APRE
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
globenewswire.com
AZN
APRE
BOLD
FHTX
Form 8-K
sec.gov
APRE
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
globenewswire.com
APRE
Form 8-K
sec.gov
APRE
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com
APRE
Aprecomm Appoints Sapna Gopinath Kizhekkeveettil as Global CHRO to Strengthen Employee Engagement and Retention
prnewswire.com
APRE
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
globenewswire.com
APRE
Form 8-K
sec.gov
APRE